nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—PTGS2—head and neck cancer	0.817	1	CbGaD
Nabumetone—Congenital anomaly—Fluorouracil—head and neck cancer	0.00376	0.0289	CcSEcCtD
Nabumetone—Developmental delay—Fluorouracil—head and neck cancer	0.00376	0.0289	CcSEcCtD
Nabumetone—Peptic ulcer—Vinblastine—head and neck cancer	0.00326	0.025	CcSEcCtD
Nabumetone—CYP1A2—Arylamine metabolism—NAT2—head and neck cancer	0.0027	0.054	CbGpPWpGaD
Nabumetone—Bullous eruption—Docetaxel—head and neck cancer	0.00261	0.0201	CcSEcCtD
Nabumetone—Rectal haemorrhage—Vinblastine—head and neck cancer	0.00241	0.0185	CcSEcCtD
Nabumetone—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—head and neck cancer	0.00226	0.0451	CbGpPWpGaD
Nabumetone—Raised liver function tests—Docetaxel—head and neck cancer	0.00224	0.0172	CcSEcCtD
Nabumetone—Hyperuricaemia—Hydroxyurea—head and neck cancer	0.00214	0.0165	CcSEcCtD
Nabumetone—Interstitial pneumonia—Docetaxel—head and neck cancer	0.00214	0.0164	CcSEcCtD
Nabumetone—Duodenal ulcer—Docetaxel—head and neck cancer	0.00214	0.0164	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—CEBPA—head and neck cancer	0.00209	0.0418	CbGpPWpGaD
Nabumetone—Blood uric acid increased—Hydroxyurea—head and neck cancer	0.00202	0.0155	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—CCNA1—head and neck cancer	0.00184	0.0368	CbGpPWpGaD
Nabumetone—Hepatic failure—Hydroxyurea—head and neck cancer	0.00161	0.0123	CcSEcCtD
Nabumetone—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.00151	0.0116	CcSEcCtD
Nabumetone—Interstitial lung disease—Docetaxel—head and neck cancer	0.00146	0.0112	CcSEcCtD
Nabumetone—Melatonin—CYP1A1—head and neck cancer	0.00138	0.579	CrCbGaD
Nabumetone—Angina pectoris—Vinblastine—head and neck cancer	0.00133	0.0102	CcSEcCtD
Nabumetone—MPO—Vitamin B12 Metabolism—SOD2—head and neck cancer	0.00131	0.0263	CbGpPWpGaD
Nabumetone—Pancreatitis—Hydroxyurea—head and neck cancer	0.00122	0.00939	CcSEcCtD
Nabumetone—Depression—Vinblastine—head and neck cancer	0.00122	0.00934	CcSEcCtD
Nabumetone—Acute coronary syndrome—Vinblastine—head and neck cancer	0.0012	0.00923	CcSEcCtD
Nabumetone—Thrombophlebitis—Fluorouracil—head and neck cancer	0.0012	0.00921	CcSEcCtD
Nabumetone—Myocardial infarction—Vinblastine—head and neck cancer	0.0012	0.00918	CcSEcCtD
Nabumetone—Photosensitivity—Fluorouracil—head and neck cancer	0.00118	0.00908	CcSEcCtD
Nabumetone—CYP1A2—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.00118	0.0236	CbGpPWpGaD
Nabumetone—Dysuria—Hydroxyurea—head and neck cancer	0.00117	0.00896	CcSEcCtD
Nabumetone—Agranulocytosis—Vinblastine—head and neck cancer	0.00114	0.00874	CcSEcCtD
Nabumetone—Weight increased—Hydroxyurea—head and neck cancer	0.00114	0.00872	CcSEcCtD
Nabumetone—Haemoglobin—Vinblastine—head and neck cancer	0.0011	0.00845	CcSEcCtD
Nabumetone—Haemorrhage—Vinblastine—head and neck cancer	0.00109	0.00841	CcSEcCtD
Nabumetone—Dermatitis bullous—Fluorouracil—head and neck cancer	0.00109	0.00835	CcSEcCtD
Nabumetone—Stomatitis—Hydroxyurea—head and neck cancer	0.00108	0.00832	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—SOD2—head and neck cancer	0.00107	0.0214	CbGpPWpGaD
Nabumetone—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.00104	0.00798	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—GPX1—head and neck cancer	0.00102	0.0204	CbGpPWpGaD
Nabumetone—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.001	0.0201	CbGpPWpGaD
Nabumetone—Haemoglobin—Hydroxyurea—head and neck cancer	0.001	0.00771	CcSEcCtD
Nabumetone—Naproxen—PTGS2—head and neck cancer	0.000999	0.421	CrCbGaD
Nabumetone—Haemorrhage—Hydroxyurea—head and neck cancer	0.000998	0.00767	CcSEcCtD
Nabumetone—Alopecia—Vinblastine—head and neck cancer	0.000967	0.00743	CcSEcCtD
Nabumetone—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.000914	0.0183	CbGpPWpGaD
Nabumetone—Dysphagia—Fluorouracil—head and neck cancer	0.000898	0.00689	CcSEcCtD
Nabumetone—Chills—Hydroxyurea—head and neck cancer	0.000896	0.00688	CcSEcCtD
Nabumetone—Ill-defined disorder—Vinblastine—head and neck cancer	0.000884	0.00679	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—IL2—head and neck cancer	0.000884	0.0177	CbGpPWpGaD
Nabumetone—Alopecia—Hydroxyurea—head and neck cancer	0.000882	0.00677	CcSEcCtD
Nabumetone—Anaemia—Vinblastine—head and neck cancer	0.000881	0.00676	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—GSTM1—head and neck cancer	0.000878	0.0176	CbGpPWpGaD
Nabumetone—Angina pectoris—Fluorouracil—head and neck cancer	0.000874	0.00672	CcSEcCtD
Nabumetone—Thrombophlebitis—Docetaxel—head and neck cancer	0.000866	0.00665	CcSEcCtD
Nabumetone—Malaise—Vinblastine—head and neck cancer	0.000859	0.0066	CcSEcCtD
Nabumetone—Vertigo—Vinblastine—head and neck cancer	0.000856	0.00657	CcSEcCtD
Nabumetone—Leukopenia—Vinblastine—head and neck cancer	0.000853	0.00655	CcSEcCtD
Nabumetone—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—head and neck cancer	0.000849	0.017	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—SOD2—head and neck cancer	0.000849	0.017	CbGpPWpGaD
Nabumetone—Hepatic failure—Docetaxel—head and neck cancer	0.000834	0.00641	CcSEcCtD
Nabumetone—Hypertension—Vinblastine—head and neck cancer	0.000823	0.00632	CcSEcCtD
Nabumetone—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000819	0.00629	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—GPX1—head and neck cancer	0.00081	0.0162	CbGpPWpGaD
Nabumetone—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000806	0.00619	CcSEcCtD
Nabumetone—Pneumonia—Fluorouracil—head and neck cancer	0.000805	0.00618	CcSEcCtD
Nabumetone—Anaemia—Hydroxyurea—head and neck cancer	0.000803	0.00617	CcSEcCtD
Nabumetone—Discomfort—Vinblastine—head and neck cancer	0.000802	0.00616	CcSEcCtD
Nabumetone—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000789	0.00606	CcSEcCtD
Nabumetone—Myocardial infarction—Fluorouracil—head and neck cancer	0.000785	0.00603	CcSEcCtD
Nabumetone—Dermatitis bullous—Docetaxel—head and neck cancer	0.000784	0.00602	CcSEcCtD
Nabumetone—Malaise—Hydroxyurea—head and neck cancer	0.000784	0.00602	CcSEcCtD
Nabumetone—Stomatitis—Fluorouracil—head and neck cancer	0.00078	0.00599	CcSEcCtD
Nabumetone—Leukopenia—Hydroxyurea—head and neck cancer	0.000778	0.00597	CcSEcCtD
Nabumetone—Thrombocytopenia—Vinblastine—head and neck cancer	0.000761	0.00585	CcSEcCtD
Nabumetone—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.00075	0.00576	CcSEcCtD
Nabumetone—Agranulocytosis—Fluorouracil—head and neck cancer	0.000747	0.00574	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—STAT3—head and neck cancer	0.000744	0.0149	CbGpPWpGaD
Nabumetone—Anorexia—Vinblastine—head and neck cancer	0.000741	0.00569	CcSEcCtD
Nabumetone—Discomfort—Hydroxyurea—head and neck cancer	0.000731	0.00561	CcSEcCtD
Nabumetone—Haemoglobin—Fluorouracil—head and neck cancer	0.000722	0.00555	CcSEcCtD
Nabumetone—Haemorrhage—Fluorouracil—head and neck cancer	0.000719	0.00552	CcSEcCtD
Nabumetone—Oedema—Hydroxyurea—head and neck cancer	0.000709	0.00545	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—BCL2—head and neck cancer	0.0007	0.014	CbGpPWpGaD
Nabumetone—Paraesthesia—Vinblastine—head and neck cancer	0.000698	0.00536	CcSEcCtD
Nabumetone—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000694	0.00533	CcSEcCtD
Nabumetone—Liver function test abnormal—Docetaxel—head and neck cancer	0.000692	0.00532	CcSEcCtD
Nabumetone—CYP1A2—Estrogen Receptor Pathway—CYP1A1—head and neck cancer	0.000681	0.0136	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—CEBPA—head and neck cancer	0.000679	0.0136	CbGpPWpGaD
Nabumetone—Anorexia—Hydroxyurea—head and neck cancer	0.000676	0.00519	CcSEcCtD
Nabumetone—Decreased appetite—Vinblastine—head and neck cancer	0.000676	0.00519	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000675	0.00518	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—PTGS2—head and neck cancer	0.000665	0.0133	CbGpPWpGaD
Nabumetone—Constipation—Vinblastine—head and neck cancer	0.000665	0.00511	CcSEcCtD
Nabumetone—Dysphagia—Docetaxel—head and neck cancer	0.000648	0.00498	CcSEcCtD
Nabumetone—Arrhythmia—Fluorouracil—head and neck cancer	0.000642	0.00493	CcSEcCtD
Nabumetone—Feeling abnormal—Vinblastine—head and neck cancer	0.000641	0.00492	CcSEcCtD
Nabumetone—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000636	0.00488	CcSEcCtD
Nabumetone—Alopecia—Fluorouracil—head and neck cancer	0.000635	0.00488	CcSEcCtD
Nabumetone—Dyspnoea—Hydroxyurea—head and neck cancer	0.000632	0.00486	CcSEcCtD
Nabumetone—Angina pectoris—Docetaxel—head and neck cancer	0.000631	0.00485	CcSEcCtD
Nabumetone—Somnolence—Hydroxyurea—head and neck cancer	0.000631	0.00484	CcSEcCtD
Nabumetone—Dyspepsia—Hydroxyurea—head and neck cancer	0.000624	0.00479	CcSEcCtD
Nabumetone—Decreased appetite—Hydroxyurea—head and neck cancer	0.000617	0.00473	CcSEcCtD
Nabumetone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000616	0.0123	CbGpPWpGaD
Nabumetone—Abdominal pain—Vinblastine—head and neck cancer	0.000615	0.00472	CcSEcCtD
Nabumetone—Fatigue—Hydroxyurea—head and neck cancer	0.000611	0.0047	CcSEcCtD
Nabumetone—Constipation—Hydroxyurea—head and neck cancer	0.000607	0.00466	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—CCNA1—head and neck cancer	0.000598	0.012	CbGpPWpGaD
Nabumetone—Weight increased—Docetaxel—head and neck cancer	0.00059	0.00453	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—PIK3CA—head and neck cancer	0.000587	0.0117	CbGpPWpGaD
Nabumetone—Weight decreased—Docetaxel—head and neck cancer	0.000586	0.0045	CcSEcCtD
Nabumetone—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000584	0.00449	CcSEcCtD
Nabumetone—Pneumonia—Docetaxel—head and neck cancer	0.000581	0.00446	CcSEcCtD
Nabumetone—Anaemia—Fluorouracil—head and neck cancer	0.000578	0.00444	CcSEcCtD
Nabumetone—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.000577	0.0115	CbGpPWpGaD
Nabumetone—Hypersensitivity—Vinblastine—head and neck cancer	0.000573	0.0044	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000573	0.0044	CcSEcCtD
Nabumetone—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00057	0.00437	CcSEcCtD
Nabumetone—Renal failure—Docetaxel—head and neck cancer	0.000568	0.00436	CcSEcCtD
Nabumetone—Myocardial infarction—Docetaxel—head and neck cancer	0.000566	0.00435	CcSEcCtD
Nabumetone—Stomatitis—Docetaxel—head and neck cancer	0.000563	0.00432	CcSEcCtD
Nabumetone—Jaundice—Docetaxel—head and neck cancer	0.000563	0.00432	CcSEcCtD
Nabumetone—Body temperature increased—Hydroxyurea—head and neck cancer	0.000561	0.00431	CcSEcCtD
Nabumetone—Leukopenia—Fluorouracil—head and neck cancer	0.00056	0.0043	CcSEcCtD
Nabumetone—Asthenia—Vinblastine—head and neck cancer	0.000558	0.00429	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—IL2—head and neck cancer	0.000556	0.0111	CbGpPWpGaD
Nabumetone—PTGS2—Overview of nanoparticle effects—BCL2—head and neck cancer	0.000556	0.0111	CbGpPWpGaD
Nabumetone—CYP1A2—Estrogen metabolism—GSTM1—head and neck cancer	0.000553	0.0111	CbGpPWpGaD
Nabumetone—PTGS1—Eicosanoid Synthesis—PTGS2—head and neck cancer	0.000552	0.011	CbGpPWpGaD
Nabumetone—Agranulocytosis—Docetaxel—head and neck cancer	0.000539	0.00414	CcSEcCtD
Nabumetone—Diarrhoea—Vinblastine—head and neck cancer	0.000532	0.00409	CcSEcCtD
Nabumetone—Discomfort—Fluorouracil—head and neck cancer	0.000526	0.00404	CcSEcCtD
Nabumetone—CYP1A2—Estrogen metabolism—CYP1A1—head and neck cancer	0.000525	0.0105	CbGpPWpGaD
Nabumetone—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000523	0.00401	CcSEcCtD
Nabumetone—Haemoglobin—Docetaxel—head and neck cancer	0.000521	0.004	CcSEcCtD
Nabumetone—PTGS1—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000521	0.0104	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—BCL2—head and neck cancer	0.000521	0.0104	CbGpPWpGaD
Nabumetone—Haemorrhage—Docetaxel—head and neck cancer	0.000519	0.00398	CcSEcCtD
Nabumetone—PTGS1—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000516	0.0103	CbGpPWpGaD
Nabumetone—Confusional state—Fluorouracil—head and neck cancer	0.000515	0.00395	CcSEcCtD
Nabumetone—Dizziness—Vinblastine—head and neck cancer	0.000514	0.00395	CcSEcCtD
Nabumetone—Oedema—Fluorouracil—head and neck cancer	0.000511	0.00392	CcSEcCtD
Nabumetone—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000511	0.00392	CcSEcCtD
Nabumetone—Asthenia—Hydroxyurea—head and neck cancer	0.000509	0.00391	CcSEcCtD
Nabumetone—Thrombocytopenia—Fluorouracil—head and neck cancer	0.0005	0.00384	CcSEcCtD
Nabumetone—Visual impairment—Docetaxel—head and neck cancer	0.0005	0.00384	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—PTGS2—head and neck cancer	0.000495	0.0099	CbGpPWpGaD
Nabumetone—Vomiting—Vinblastine—head and neck cancer	0.000494	0.0038	CcSEcCtD
Nabumetone—Erythema multiforme—Docetaxel—head and neck cancer	0.00049	0.00377	CcSEcCtD
Nabumetone—Headache—Vinblastine—head and neck cancer	0.000487	0.00374	CcSEcCtD
Nabumetone—Anorexia—Fluorouracil—head and neck cancer	0.000487	0.00374	CcSEcCtD
Nabumetone—Diarrhoea—Hydroxyurea—head and neck cancer	0.000485	0.00373	CcSEcCtD
Nabumetone—CYP1A2—Xenobiotics—CYP1A1—head and neck cancer	0.000482	0.00965	CbGpPWpGaD
Nabumetone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—head and neck cancer	0.000477	0.00955	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—PTGS2—head and neck cancer	0.000477	0.00954	CbGpPWpGaD
Nabumetone—Dizziness—Hydroxyurea—head and neck cancer	0.000469	0.0036	CcSEcCtD
Nabumetone—Chills—Docetaxel—head and neck cancer	0.000465	0.00357	CcSEcCtD
Nabumetone—CYP1A2—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000464	0.00928	CbGpPWpGaD
Nabumetone—Arrhythmia—Docetaxel—head and neck cancer	0.000463	0.00356	CcSEcCtD
Nabumetone—Nausea—Vinblastine—head and neck cancer	0.000462	0.00355	CcSEcCtD
Nabumetone—Insomnia—Fluorouracil—head and neck cancer	0.000462	0.00355	CcSEcCtD
Nabumetone—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—head and neck cancer	0.000462	0.00924	CbGpPWpGaD
Nabumetone—Paraesthesia—Fluorouracil—head and neck cancer	0.000458	0.00352	CcSEcCtD
Nabumetone—Alopecia—Docetaxel—head and neck cancer	0.000458	0.00352	CcSEcCtD
Nabumetone—Dyspnoea—Fluorouracil—head and neck cancer	0.000455	0.0035	CcSEcCtD
Nabumetone—Somnolence—Fluorouracil—head and neck cancer	0.000454	0.00349	CcSEcCtD
Nabumetone—Vomiting—Hydroxyurea—head and neck cancer	0.000451	0.00346	CcSEcCtD
Nabumetone—Dyspepsia—Fluorouracil—head and neck cancer	0.000449	0.00345	CcSEcCtD
Nabumetone—Rash—Hydroxyurea—head and neck cancer	0.000447	0.00343	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—CCND1—head and neck cancer	0.000447	0.00895	CbGpPWpGaD
Nabumetone—Dermatitis—Hydroxyurea—head and neck cancer	0.000447	0.00343	CcSEcCtD
Nabumetone—Headache—Hydroxyurea—head and neck cancer	0.000444	0.00341	CcSEcCtD
Nabumetone—Decreased appetite—Fluorouracil—head and neck cancer	0.000444	0.00341	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—CYP1A1—head and neck cancer	0.000438	0.00876	CbGpPWpGaD
Nabumetone—Nausea—Hydroxyurea—head and neck cancer	0.000421	0.00324	CcSEcCtD
Nabumetone—Feeling abnormal—Fluorouracil—head and neck cancer	0.000421	0.00323	CcSEcCtD
Nabumetone—Anaemia—Docetaxel—head and neck cancer	0.000417	0.0032	CcSEcCtD
Nabumetone—PTGS2—S1P1 pathway—VEGFA—head and neck cancer	0.000416	0.00832	CbGpPWpGaD
Nabumetone—PTGS2—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000414	0.00828	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—NAT2—head and neck cancer	0.00041	0.0082	CbGpPWpGaD
Nabumetone—PTGS2—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000409	0.00819	CbGpPWpGaD
Nabumetone—Urticaria—Fluorouracil—head and neck cancer	0.000406	0.00311	CcSEcCtD
Nabumetone—Syncope—Docetaxel—head and neck cancer	0.000405	0.00311	CcSEcCtD
Nabumetone—Leukopenia—Docetaxel—head and neck cancer	0.000404	0.0031	CcSEcCtD
Nabumetone—Body temperature increased—Fluorouracil—head and neck cancer	0.000404	0.0031	CcSEcCtD
Nabumetone—Palpitations—Docetaxel—head and neck cancer	0.000399	0.00306	CcSEcCtD
Nabumetone—Loss of consciousness—Docetaxel—head and neck cancer	0.000397	0.00305	CcSEcCtD
Nabumetone—Cough—Docetaxel—head and neck cancer	0.000394	0.00303	CcSEcCtD
Nabumetone—PTGS2—S1P1 pathway—MAPK3—head and neck cancer	0.000393	0.00787	CbGpPWpGaD
Nabumetone—Hypertension—Docetaxel—head and neck cancer	0.00039	0.00299	CcSEcCtD
Nabumetone—Hypersensitivity—Fluorouracil—head and neck cancer	0.000376	0.00289	CcSEcCtD
Nabumetone—Dry mouth—Docetaxel—head and neck cancer	0.000376	0.00289	CcSEcCtD
Nabumetone—PTGS2—S1P1 pathway—MAPK1—head and neck cancer	0.000374	0.00749	CbGpPWpGaD
Nabumetone—Confusional state—Docetaxel—head and neck cancer	0.000372	0.00285	CcSEcCtD
Nabumetone—Oedema—Docetaxel—head and neck cancer	0.000368	0.00283	CcSEcCtD
Nabumetone—Anaphylactic shock—Docetaxel—head and neck cancer	0.000368	0.00283	CcSEcCtD
Nabumetone—Shock—Docetaxel—head and neck cancer	0.000363	0.00278	CcSEcCtD
Nabumetone—PTGS1—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000361	0.00723	CbGpPWpGaD
Nabumetone—Pruritus—Fluorouracil—head and neck cancer	0.000361	0.00277	CcSEcCtD
Nabumetone—Thrombocytopenia—Docetaxel—head and neck cancer	0.000361	0.00277	CcSEcCtD
Nabumetone—CYP1A2—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.000358	0.00717	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—TP53—head and neck cancer	0.000357	0.00715	CbGpPWpGaD
Nabumetone—Anorexia—Docetaxel—head and neck cancer	0.000351	0.0027	CcSEcCtD
Nabumetone—Diarrhoea—Fluorouracil—head and neck cancer	0.000349	0.00268	CcSEcCtD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—head and neck cancer	0.000349	0.00698	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—SOD2—head and neck cancer	0.000347	0.00695	CbGpPWpGaD
Nabumetone—Dizziness—Fluorouracil—head and neck cancer	0.000338	0.00259	CcSEcCtD
Nabumetone—Insomnia—Docetaxel—head and neck cancer	0.000333	0.00256	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—GPX1—head and neck cancer	0.000331	0.00663	CbGpPWpGaD
Nabumetone—Paraesthesia—Docetaxel—head and neck cancer	0.000331	0.00254	CcSEcCtD
Nabumetone—Dyspnoea—Docetaxel—head and neck cancer	0.000329	0.00252	CcSEcCtD
Nabumetone—Somnolence—Docetaxel—head and neck cancer	0.000328	0.00252	CcSEcCtD
Nabumetone—Vomiting—Fluorouracil—head and neck cancer	0.000325	0.00249	CcSEcCtD
Nabumetone—Dyspepsia—Docetaxel—head and neck cancer	0.000324	0.00249	CcSEcCtD
Nabumetone—Rash—Fluorouracil—head and neck cancer	0.000322	0.00247	CcSEcCtD
Nabumetone—Dermatitis—Fluorouracil—head and neck cancer	0.000322	0.00247	CcSEcCtD
Nabumetone—Decreased appetite—Docetaxel—head and neck cancer	0.00032	0.00246	CcSEcCtD
Nabumetone—Headache—Fluorouracil—head and neck cancer	0.00032	0.00246	CcSEcCtD
Nabumetone—Fatigue—Docetaxel—head and neck cancer	0.000318	0.00244	CcSEcCtD
Nabumetone—CYP1A2—Estrogen Receptor Pathway—STAT3—head and neck cancer	0.000316	0.00632	CbGpPWpGaD
Nabumetone—Constipation—Docetaxel—head and neck cancer	0.000315	0.00242	CcSEcCtD
Nabumetone—CYP1A2—Phase II conjugation—NAT2—head and neck cancer	0.000315	0.0063	CbGpPWpGaD
Nabumetone—PTGS1—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000307	0.00614	CbGpPWpGaD
Nabumetone—Feeling abnormal—Docetaxel—head and neck cancer	0.000304	0.00233	CcSEcCtD
Nabumetone—Nausea—Fluorouracil—head and neck cancer	0.000303	0.00233	CcSEcCtD
Nabumetone—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000301	0.00231	CcSEcCtD
Nabumetone—Body temperature increased—Docetaxel—head and neck cancer	0.000291	0.00224	CcSEcCtD
Nabumetone—Abdominal pain—Docetaxel—head and neck cancer	0.000291	0.00224	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—GSTM1—head and neck cancer	0.000285	0.00571	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—HRAS—head and neck cancer	0.000282	0.00564	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—SOD2—head and neck cancer	0.000276	0.00552	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.000274	0.00548	CbGpPWpGaD
Nabumetone—Hypersensitivity—Docetaxel—head and neck cancer	0.000271	0.00208	CcSEcCtD
Nabumetone—Asthenia—Docetaxel—head and neck cancer	0.000264	0.00203	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—GPX1—head and neck cancer	0.000263	0.00527	CbGpPWpGaD
Nabumetone—Pruritus—Docetaxel—head and neck cancer	0.000261	0.002	CcSEcCtD
Nabumetone—Diarrhoea—Docetaxel—head and neck cancer	0.000252	0.00194	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.000249	0.00498	CbGpPWpGaD
Nabumetone—CYP1A2—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000248	0.00496	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—head and neck cancer	0.000248	0.00496	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—head and neck cancer	0.000248	0.00496	CbGpPWpGaD
Nabumetone—Dizziness—Docetaxel—head and neck cancer	0.000244	0.00187	CcSEcCtD
Nabumetone—Vomiting—Docetaxel—head and neck cancer	0.000234	0.0018	CcSEcCtD
Nabumetone—CYP1A2—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000234	0.00468	CbGpPWpGaD
Nabumetone—Rash—Docetaxel—head and neck cancer	0.000232	0.00178	CcSEcCtD
Nabumetone—Dermatitis—Docetaxel—head and neck cancer	0.000232	0.00178	CcSEcCtD
Nabumetone—CYP1A2—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000232	0.00464	CbGpPWpGaD
Nabumetone—Headache—Docetaxel—head and neck cancer	0.000231	0.00177	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—head and neck cancer	0.000226	0.00452	CbGpPWpGaD
Nabumetone—Nausea—Docetaxel—head and neck cancer	0.000219	0.00168	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	0.000205	0.0041	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—GSTM1—head and neck cancer	0.000203	0.00405	CbGpPWpGaD
Nabumetone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.0002	0.00401	CbGpPWpGaD
Nabumetone—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000198	0.00395	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—PTGS2—head and neck cancer	0.000195	0.0039	CbGpPWpGaD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—head and neck cancer	0.000193	0.00386	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—CYP1A1—head and neck cancer	0.000192	0.00384	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	0.000185	0.00369	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	0.000185	0.00369	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—NAT2—head and neck cancer	0.000184	0.00369	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—NAT2—head and neck cancer	0.000182	0.00364	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—BCL2—head and neck cancer	0.000169	0.00339	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—UROD—head and neck cancer	0.000169	0.00338	CbGpPWpGaD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000162	0.00325	CbGpPWpGaD
Nabumetone—CYP1A2—Phase II conjugation—GSTM1—head and neck cancer	0.000156	0.00311	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.00015	0.00299	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	0.000148	0.00296	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—head and neck cancer	0.000147	0.00295	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—CCND1—head and neck cancer	0.000145	0.00291	CbGpPWpGaD
Nabumetone—CYP1A2—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000138	0.00276	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	0.000137	0.00273	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—UROD—head and neck cancer	0.000134	0.00268	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000131	0.00262	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	0.000116	0.00232	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IL2—head and neck cancer	0.000114	0.00227	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CCND1—head and neck cancer	0.000111	0.00222	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	0.000104	0.00209	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	0.000104	0.00209	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	0.000104	0.00209	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000104	0.00208	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	0.000102	0.00205	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—HRAS—head and neck cancer	9.15e-05	0.00183	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MAPK3—head and neck cancer	9.13e-05	0.00183	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—GSTM1—head and neck cancer	9.1e-05	0.00182	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—GSTM1—head and neck cancer	8.97e-05	0.0018	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	8.77e-05	0.00176	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MAPK1—head and neck cancer	8.69e-05	0.00174	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—EGFR—head and neck cancer	8.68e-05	0.00174	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—CYP1A1—head and neck cancer	8.62e-05	0.00173	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—CYP1A1—head and neck cancer	8.51e-05	0.0017	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	8.38e-05	0.00168	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—UROD—head and neck cancer	7.59e-05	0.00152	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	7.53e-05	0.00151	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	7.45e-05	0.00149	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	7.37e-05	0.00148	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TP53—head and neck cancer	7.29e-05	0.00146	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	7.27e-05	0.00145	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NAT2—head and neck cancer	7.01e-05	0.0014	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	6.56e-05	0.00131	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	6.21e-05	0.00124	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—DPYD—head and neck cancer	6.15e-05	0.00123	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	5.91e-05	0.00118	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	5.91e-05	0.00118	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	5.91e-05	0.00118	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	5.89e-05	0.00118	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	5.85e-05	0.00117	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—YAP1—head and neck cancer	5.83e-05	0.00117	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NAT2—head and neck cancer	5.57e-05	0.00111	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	5.13e-05	0.00103	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	4.96e-05	0.000993	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—DPYD—head and neck cancer	4.88e-05	0.000977	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—YAP1—head and neck cancer	4.63e-05	0.000927	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	4.38e-05	0.000877	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	4.19e-05	0.000838	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	3.82e-05	0.000765	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—TYMS—head and neck cancer	3.5e-05	0.000701	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTM1—head and neck cancer	3.46e-05	0.000693	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.35e-05	0.000669	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GPX1—head and neck cancer	3.32e-05	0.000664	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.31e-05	0.000663	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP1A1—head and neck cancer	3.28e-05	0.000657	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NAT2—head and neck cancer	3.15e-05	0.00063	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	3.04e-05	0.000607	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—TYMS—head and neck cancer	2.78e-05	0.000557	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—DPYD—head and neck cancer	2.76e-05	0.000553	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTM1—head and neck cancer	2.75e-05	0.00055	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.7e-05	0.00054	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GPX1—head and neck cancer	2.63e-05	0.000527	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—YAP1—head and neck cancer	2.62e-05	0.000524	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP1A1—head and neck cancer	2.61e-05	0.000522	CbGpPWpGaD
Nabumetone—PTGS2—Disease—NOTCH1—head and neck cancer	2.49e-05	0.000499	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.14e-05	0.000428	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.97e-05	0.000394	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTGS2—head and neck cancer	1.95e-05	0.000391	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.72e-05	0.000344	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTEN—head and neck cancer	1.7e-05	0.000341	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PTEN—head and neck cancer	1.61e-05	0.000323	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—TYMS—head and neck cancer	1.57e-05	0.000315	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTM1—head and neck cancer	1.56e-05	0.000311	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GPX1—head and neck cancer	1.49e-05	0.000298	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP1A1—head and neck cancer	1.47e-05	0.000295	CbGpPWpGaD
Nabumetone—PTGS2—Disease—STAT3—head and neck cancer	1.44e-05	0.000289	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MAPK3—head and neck cancer	1.38e-05	0.000276	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PTEN—head and neck cancer	1.35e-05	0.00027	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MAPK1—head and neck cancer	1.31e-05	0.000263	CbGpPWpGaD
Nabumetone—PTGS2—Disease—EGFR—head and neck cancer	1.31e-05	0.000263	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.21e-05	0.000242	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CA—head and neck cancer	1.2e-05	0.00024	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PIK3CA—head and neck cancer	1.14e-05	0.000228	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HRAS—head and neck cancer	1.05e-05	0.000211	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—AKT1—head and neck cancer	9.81e-06	0.000196	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CA—head and neck cancer	9.54e-06	0.000191	CbGpPWpGaD
Nabumetone—PTGS2—Disease—AKT1—head and neck cancer	9.3e-06	0.000186	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTGS2—head and neck cancer	8.77e-06	0.000176	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—AKT1—head and neck cancer	7.79e-06	0.000156	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTEN—head and neck cancer	7.65e-06	0.000153	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CA—head and neck cancer	5.4e-06	0.000108	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—AKT1—head and neck cancer	4.41e-06	8.82e-05	CbGpPWpGaD
